# Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

> **NCT01037127** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 97 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK1120212

## Key facts

- **NCT ID:** NCT01037127
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-07
- **Final completion:** 2013-01
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2014-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037127, "Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01037127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*